Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent

a technology of muscarinic receptors and compositions, applied in the direction of antinoxious agents, phosphorous compound active ingredients, peptide/protein ingredients, etc., can solve the problems of affecting the ability of muscarinic receptors, damage to cellular receptors and other cellular components, damage or death of cells, etc., to improve memory and cognition, treat or prevent brain deterioration or cognitive and memory loss associated effects

Inactive Publication Date: 2006-01-12
HEALTHPARTNERS RESEACH FOUND
View PDF5 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] The method of the invention can treat or prevent a CNS disorder. Preferably, the method of the invention can treat or prevent neurodegeneration, can improve memory and cognition, can treat or prevent brain deterioration or cognitive and memory loss associated with aging, or can treat or prevent Alzheimer's Disease, Parkinson's disease, Lewy body dementia, multiple sclerosis, cerebellar ataxia, progressive supranuclear palsy, amyotrophic lateral sclerosis, affective disorders, anxiety disorders, and / or schizophrenia; nerve damage from cerebrovascular disorders such as stroke or atherosclerosis in the brain or spinal cord, from CNS infections including meningitis and HIV, from tumors of the brain and spinal cord, prion diseases, and CNS disorders resulting from ordinary aging (e.g., anosmia), brain injury, or spinal cord injury.
[0013] In another embodiment, the method of the invention can treat or prevent a disease or disorder not of the CNS. Preferably, the method of the invention can treat or prevent cancer, or neuropathies or diseases or disorders of the heart, smooth muscles, blood, blood vessels, glands, or bones. Such diseases or disorders include hypertension, myocardial infarction, ischemic heart disease, congestive heart failure, cardiac arrhythmias, cancer, irritable bowel syndrome, diverticular disease, urinary incontinence, esophageal achalasia, chronic obstructive airways disease, xerostomia, diabetes mellitus, Sjogren's syndrome or dry eye syndrome which involves decreased secretion of tears by, for example, the lacrimal glands, Paget's disease, hereditary hematochromatosis or a non-CNS disorder resulting from normal aging.

Problems solved by technology

Often as a result of damage, the ability of cellular receptors to interact with or bind various agents is decreased, resulting in an impairment of vital intrinsic and extrinsic communication.
Damage to cellular receptors and other cellular components diminishes the ability of a receptor to bind agents and elicit a communication or signaling event.
This can result in damage or death to cells, resulting in damage or diseases of tissues, organs and living systems.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
  • Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
  • Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

Protection of Muscarinic Acetylcholine Receptor (mAChR) in Cell Free Systems

Materials and Methods

Membrane mAChR Preparation

[0104] Membranes rich in mAChRs were prepared by a modification of the method used by Marks and Collins (Characterization of nicotine binding in mouse brain and comparison with the binding of a-bungarotoxin and quinuclindinyl benzilate, Mol. Pharmacol. 22:544-564, 1982). Gray matter from nondemented adult human frontal cortex was homogenized in 9 vol of 50 mM Tris-HCl, pH 7.4, using 5 passes of a glass / Teflon motor-driven homogenizer. The homogenate was centrifuged at 27 000×g for 20 mm at 4° C., and the subsequent pellet resuspended in 9 vol of cold deionized water with 5 passes of the homogenizer. The resuspension was incubated at 37° C. for 5 min, then was centrifuged as before. The resulting pellet was resuspended, incubated and centrifuged again as above. The final pellet was weighed, resuspended at 15% w / v in 50 mM Tris-HCl buffer, aliquoted in small ...

example 2

Protection of the mAChR in Cell Culture

[0121] Various systems for determining the protection of a mAChR in cell culture are known in the art. Such cell culture systems can be used to determine if mAChR is protected from a damaging agent or condition according to the method of the invention. For example, by administering a mAChR antagonist or agonist alone or in combination with one or more protective agent and / or one or more pyrophosphate analog, one of skill in the art can determine if a mAChR is protected by the one or more protective agent and / or one or more pyrophosphate analog.

example 3

Protection of the mAChR Receptor in Animals

[0122] Various systems for determining the protection of a mAChR in animals are known in the art. Such animal systems can be used to determine if mAChR is protected according to the method of the invention. For example, by administering a mAChR antagonist or agonist alone or in combination with one or more protective agents and / or one or more pyrophosphate analogs, one of skill in the art can determine if a mAChR is protected by the one or more protective agents and / or one or more pyrophosphate analogs.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
pHaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Methods and compositions for protecting muscarinic receptor(s) in a subject by administering at least one protective agent alone, in combination with other protective agents, or in combination with at least one neurologic agent.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of provisional application No. 60 / 200,843 filed May 1, 2000; provisional application No. 60 / 233,263 filed Sep. 6, 2000; and provisional application No. 60 / 233,025 filed Sep. 15, 2000; each entitled “Methods and Compositions for Enhancing Cellular Function and Protecting Receptor.”BACKGROUND OF THE INVENTION [0002] Cellular function depends on the maintenance of intact cellular components including: receptors, proteins, lipids, nucleic acids, carbohydrates, hormones and cofactors. Cellular receptors, including cell surface receptors, mediate communication within and between cells, tissues and organs within a living system. Cellular receptors also provide a means to signal a living system, tissues, organs, cells, and subcellular compartments. Receptors are molecules or macromolecules that bind or interact with agents to alter or enhance their function. Many receptors are membrane bound proteins, which r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7076A61K31/7072A61K31/663A61K31/352A61K31/409A61K31/66A61K31/708A61K31/7084A61K31/7105A61K38/17A61K45/06A61P33/00
CPCA61K31/352A61K31/409A61K31/66A61K31/661A61K31/6615A61K31/662A61K45/06A61K31/7072A61K31/7076A61K31/708A61K31/7084A61K31/7105A61K31/663A61K2300/00A61P25/00A61P25/28A61P33/00A61P35/00A61P39/00A61P39/06A61P9/00
Inventor FREY, WILLIAM H. IIFAWCETT, JOHN RANDALL
Owner HEALTHPARTNERS RESEACH FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products